Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL2846 versus placebo in previously VEGFR-targeted advanced radioactive iodine-refractory differentiated thyroid cancer
CTR20244888Phase 3Active
- Sponsor
- IDEXX Ningxin
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vilzemetkib in well-differentiated thyroid cancer (WDTC), sponsored by IDEXX Ningxin. Started Apr 2025; status: active.
02
Drugs
vilzemetkib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on CTR20244888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244888.